IGEA Pharma N.V.

IGEA to get SIX approval to delay the 2021 annual report disclosure

IGEA Pharma N.V. / Key word(s): Annual Results IGEA Pharma N.V.: IGEA to get SIX approval to delay the 2021 annual report disclosure 02-May-2022 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. IGEA to get SIX approval to delay the 2021 annual report disclosure

Hoofddorp, the Netherlands, 2 May 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.

As anticipated on 29 April 2022, further to the issuance of the new shares related to the business combination happened and approved on September 27^th 2021, the Company is in the process to review with the statutory auditors all financial statements and certain items are still under analysis, while certain changes in the corporate governance have been approved, required to have all implications of such matters on the Company's reporting obligations adequately presented, leading to a delay in disclosing the 2021 annual report. IGEA expects to disclose its 2021 annual report within the next coming weeks.

In accordance with SIX's approval, this press release sets out the relevant section of the decision:

"I. The exemption application of IGEA Pharma N.V. (Issuer) dated 29 April 2022 requesting an extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 15 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):

a. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual report is not published in accordance

 

with the provisions

on ad hoc publicity (Art. 53 of the Listing Rules [LR] in

connection with the Directive on Ad hoc Publicity [DAH]) and not filed with SIX Exchange Regulation AG until Wednesday, 15 June 2022, 11.59 pm CET, at the latest.

b. IGEA Pharma N.V. is required to publish a notice in accordance with the provisions of ad hoc publicity (art. 53 LR in connection with the DAH) concerning this decision until Monday, 2 May 2022, 7.30 am CET, at the latest. The notice must contain: